Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336235 | 0.87 | ACP1 (0.60) | ACP1ALDH1A1KDM4EPPARGESR1 | |
| SCHEMBL2330828 | 0.86 | PPARG (0.54) | ALDH1A1TSHRKDM4EPPARGAKR1B1 | |
| SCHEMBL2334482 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM4EPPARGAKR1B1 | |
| SCHEMBL4681189 | 0.79 | ALDH1A1 (0.73) | ALDH1A1TSHRKDM4EAKR1B1GAA | |
| SCHEMBL2334837 | 0.79 | ESR1 (0.67) | ALDH1A1TSHRKDM4EPPARGAKR1B1 | |
| SCHEMBL11553562 | 0.76 | ALDH1A1 (0.62) | ALDH1A1TSHRKDM4ETNKSGAA | |
| SCHEMBL2337021 | 0.75 | PPARG (0.56) | ACP1ALDH1A1KDM4EPPARGESR1 | |
| SCHEMBL10624618 | 0.74 | ALDH1A1 (0.52) | ALDH1A1TSHRKDM4ETNKSGAA | |
| SCHEMBL3646805 | 0.73 | ALDH1A1 (0.64) | ALDH1A1TSHRKDM4EAKR1B1GAA | |
| SCHEMBL9147000 | 0.73 | AKR1B1 (0.58) | ALDH1A1TSHRKDM4EAKR1B1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9717706-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC | 2015-12-10 | — | — | US | disclosed |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2533637-B1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8669381-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8481590-B2 | Chromone inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2533637-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011099978-A1 | CHROMONE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352073-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ACP1 3228/4885ALDH1A1 363/4885TSHR 887/4885 |
| US-20130274320-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ACP1 3228/4885ALDH1A1 363/4885TSHR 887/4885 |
| US-20140163092-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ACP1 3228/4885ALDH1A1 363/4885TSHR 887/4885 |
| US-20120295966-A1 | Chromone Inhibitors of S-Nitrosoglutathione Reductase | POR, GSR, CBR1 | ACP1 3228/4885ALDH1A1 363/4885TSHR 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.